Publications
321 results found
Podlekareva D, Mocroft A, Dragsted UB, et al., 2006, Factors associated with the development of opportunistic infections in HIV-1-infected adults with high CD4<SUP>+</SUP> cell counts:: A EuroSIDA study, JOURNAL OF INFECTIOUS DISEASES, Vol: 194, Pages: 633-641, ISSN: 0022-1899
- Author Web Link
- Cite
- Citations: 62
Yeni P, Cooper DA, Aboulker J-P, et al., 2006, Virological and immunological outcomes at 3 years after starting antiretroviral therapy with regimens containing non-nucleoside reverse transcriptase inhibitor, protease inhibitor, or both in INITIO: open-label randomised trial, LANCET, Vol: 368, Pages: 287-298, ISSN: 0140-6736
- Author Web Link
- Cite
- Citations: 77
Frater AJ, Edwards CTT, McCarthy N, et al., 2006, Passive sexual transmission of human immunodeficiency virus type 1 variants and adaptation in new hosts, JOURNAL OF VIROLOGY, Vol: 80, Pages: 7226-7234, ISSN: 0022-538X
- Author Web Link
- Cite
- Citations: 22
Lacey CJN, Wright A, Weber JN, et al., 2006, Direct measurement of in-vivo vaginal microbicide levels of PRO 2000 achieved in a human safety study, AIDS, Vol: 20, Pages: 1027-1030, ISSN: 0269-9370
- Author Web Link
- Cite
- Citations: 25
Snoeck J, Kantor R, Shafer RW, et al., 2006, Discordances between interpretation algorithms for genotypic resistance to protease and reverse transcriptase inhibitors of human immunodeficiency virus are subtype dependent., Antimicrob Agents Chemother, Vol: 50, Pages: 694-701, ISSN: 0066-4804
The major limitation of drug resistance genotyping for human immunodeficiency virus remains the interpretation of the results. We evaluated the concordance in predicting therapy response between four different interpretation algorithms (Rega 6.3, HIVDB-08/04, ANRS [07/04], and VGI 8.0). Sequences were gathered through a worldwide effort to establish a database of non-B subtype sequences, and demographic and clinical information about the patients was gathered. The most concordant results were found for nonnucleoside reverse transcriptase (RT) inhibitors (93%), followed by protease inhibitors (84%) and nucleoside RT inhibitor (NRTIs) (76%). For therapy-naive patients, for nelfinavir, especially for subtypes C and G, the discordances were driven mainly by the protease (PRO) mutational pattern 82I/V + 63P + 36I/V for subtype C and 82I + 63P + 36I + 20I for subtype G. Subtype F displayed more discordances for ritonavir in untreated patients due to the combined presence of PRO 20R and 10I/V. In therapy-experienced patients, subtype G displayed a lot of discordances for saquinavir and indinavir due to mutational patterns involving PRO 90 M and 82I. Subtype F had more discordance for nelfinavir attributable to the presence of PRO 88S and 82A + 54V. For the NRTIs lamivudine and emtricitabine, CRF01_AE had more discordances than subtype B due to the presence of RT mutational patterns 65R + 115 M and 118I + 215Y, respectively. Overall, the different algorithms agreed well on the level of resistance scored, but some of the discordances could be attributed to specific (subtype-dependent) combinations of mutations. It is not yet known whether therapy response is subtype dependent, but the advice given to clinicians based on a genotypic interpretation algorithm differs according to the subtype.
Fox JM, Fidler S, Weber J, 2006, Resistance to HIV drugs in UK may be lower in some areas, BRITISH MEDICAL JOURNAL, Vol: 332, Pages: 179-180, ISSN: 0959-8146
- Author Web Link
- Cite
- Citations: 6
Fidler S, Fraser C, Fox J, et al., 2006, Comparative potency of three antiretroviral therapy regimes in primary HIV infection., AIDS.
Cane P, Chrystie I, Dunn D, et al., 2005, Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study, BMJ-BRITISH MEDICAL JOURNAL, Vol: 331, Pages: 1368-1371, ISSN: 1756-1833
- Author Web Link
- Cite
- Citations: 146
Scriba T, Purbhoo M, Day CL, et al., 2005, Ultrasensitive detection and phenotyping of CD4+ T cells with optimized HLA class II tetramer staining., J Immunology, Vol: 175, Pages: 6334-6343
Milicic A, Edwards C, Hue S, et al., 2005, Sexual transmission of single human immunodeficiency virus type 1 virions encoding highly polymorphic multisite cytotoxic T-lymphocyte escape variants., Journal of Virology, Vol: 79, Pages: 13953-13962, ISSN: 0022-538X
Weber J, Desai K, Darbyshire J, 2005, The development of vaginal microbicides for the prevention of HIV transmission, PLoS Medicine, Vol: 2, Pages: 392-395, ISSN: 1549-1277
Microbicides are chemical agents used topically by women within the vagina in order to prevent infection by HIV and potentially by other enveloped viruses and sexually transmitted pathogens. Prototype microbicides are designed to be inserted prior to each act of sexual intercourse and could also be contraceptive, although most current potential microbicides are not. Several proof-of-principle phase III trials of candidate microbicides are currently in progress or are shortly to commence, and a definitive answer to their efficacy and safety is anticipated by 2008.
Kantor R, Katzenstein DA, Efron B, et al., 2005, Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration, PLoS Medicine, Vol: 2, Pages: 325-337, ISSN: 1549-1277
Background:The genetic differences among HIV-1 subtypes may be critical to clinical management anddrug resistance surveillance as antiretroviral treatment is expanded to regions of the worldwhere diverse non-subtype-B viruses predominate.Methods and Findings:To assess the impact of HIV-1 subtype and antiretroviral treatment on the distribution ofmutations in protease and reverse transcriptase, a binomial response model using subtype andtreatment as explanatory variables was used to analyze a large compiled dataset of non-subtype-B HIV-1 sequences. Non-subtype-B sequences from 3,686 persons with wellcharacterized antiretroviral treatment histories were analyzed in comparison to subtype Bsequences from 4,769 persons. The non-subtype-B sequences included 461 with subtype A,1,185 with C, 331 with D, 245 with F, 293 with G, 513 with CRF01_AE, and 618 with CRF02_AG.Each of the 55 known subtype B drug-resistance mutations occurred in at least one non-Bisolate, and 44 (80%) of these mutations were significantly associated with antiretroviraltreatment in at least one non-B subtype. Conversely, of 67 mutations found to be associatedwith antiretroviral therapy in at least one non-B subtype, 61 were also associated withantiretroviral therapy in subtype B isolates.Conclusion:Global surveillance and genotypic assessment of drug resistance should focus primarily onthe known subtype B drug-resistance mutations.
Bobkov AF, Selimova LM, Khanina TA, et al., 2005, Human immunodeficiency virus type 1 in illicit-drug solutions used intravenously retains infectivity, JOURNAL OF CLINICAL MICROBIOLOGY, Vol: 43, Pages: 1937-1939, ISSN: 0095-1137
- Author Web Link
- Cite
- Citations: 6
Blackham J, Burns S, Cameron S, et al., 2005, Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice, AIDS, Vol: 19, Pages: 487-494, ISSN: 0269-9370
- Author Web Link
- Cite
- Citations: 81
Olsen CH, Gatell J, Ledergerber B, et al., 2005, Risk of AIDS and death at given HIV-RNA and CD4 cell counts, in relation to specific antiretroviral drugs in the regimen, AIDS, Vol: 19, Pages: 319-330, ISSN: 0269-9370
- Author Web Link
- Cite
- Citations: 49
Scriba T, zhang HT, Brown HL, et al., 2005, HIV-1-specific CD4+ T lymphocyte turnover and activation increase upon viral rebound., J Clin Invest, Vol: 115, Pages: 443-450
Taylor GP, Bodéus M, Courtois F, et al., 2005, The seroepidemiology of human T-lymphotropic viruses -: Types I and II in Europe:: A prospective study of pregnant women, JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, Vol: 38, Pages: 104-109, ISSN: 1525-4135
- Author Web Link
- Cite
- Citations: 54
Deforche K, Camacho R, Grossman Z, et al., 2005, Interactions between nevirapine resistance mutations and NRTI resistance mutations, 14th International HIV Drug Resistance Workshop, Publisher: INT MEDICAL PRESS LTD, Pages: S144-S144, ISSN: 1359-6535
Beddows S, Zheng NN, Herrera C, et al., 2005, Neutralization sensitivity of HIV-1 Env-pseudotyped virus clones is determined by co-operativity between mutations which modulate the CD4-binding site and those that affect gp120-gp41 stability, Virology, Vol: 337, Pages: 136-148
Adaptation of antibody neutralization-resistant human immunodeficiency virus type I (HIV-1) to growth in vitro generally results in the acquisition of a neutralization-sensitive phenotype, an alteration of viral growth kinetics, and an array of amino acid substitutions associated with these changes. Here we examine a panel of Env chimeras and mutants derived from these neutralization-resistant and -sensitive parental Envs. A range of neutralization and infectivity phenotypes was observed. These included a modulation of the CD4 binding site (CD4bs) towards recognition by neutralizing and non-neutralizing CD4bs-directed antibodies, resulting in a globally neutralization-sensitive Env; alterations which affected Env complex stability; and interactions which resulted in differential infectivity and CCR5/CXCR4 usage. This range of properties resulted from the complex interactions of no more than three amino acids found in key Env locations. These data add to a growing body of evidence that dramatic functional alterations of the native oligomeric Env protein complex can result from relatively minor amino acid substitutions.
Kantor R, DeLong A, Shafer RW, et al., 2005, Selection of resistance following first-line anti-retroviral regimens among HIV-1 subtypes, 14th International HIV Drug Resistance Workshop, Publisher: INT MEDICAL PRESS LTD, Pages: S146-S146, ISSN: 1359-6535
- Author Web Link
- Cite
- Citations: 1
Kantor R, DeLong A, Shafer RW, et al., 2005, Selection of resistance following first-line antiretroviral regimens among HIV-1 subtypes, 14th International HIV Drug Resistance Workshop, Publisher: INT MEDICAL PRESS LTD, Pages: S146-S146, ISSN: 1359-6535
- Author Web Link
- Cite
- Citations: 1
Deforche K, Camacho R, Grossman Z, et al., 2005, Interactions between nevirapine resistance mutations and NRTI resistance mutations, 14th International HIV Drug Resistance Workshop, Publisher: INT MEDICAL PRESS LTD, Pages: S144-S144, ISSN: 1359-6535
Deforche K, Camacho R, Grossman Z, et al., 2005, Mapping nevirapine and efavirenz resistance using Bayesian networks of HIV-1 <i>pol</i> sequences of subtypes A, B, C, F and G, 14th International HIV Drug Resistance Workshop, Publisher: INT MEDICAL PRESS LTD, Pages: S132-S132, ISSN: 1359-6535
- Author Web Link
- Cite
- Citations: 2
Deforche K, Camacho R, Grossman Z, et al., 2005, Mapping nevirapine and efavirenz resistance using Bayesian networks of HIV-1 <i>pol</i> sequences of subtypes A, B, C, F and G, 14th International HIV Drug Resistance Workshop, Publisher: INT MEDICAL PRESS LTD, Pages: S132-S132, ISSN: 1359-6535
- Author Web Link
- Cite
- Citations: 2
Ward H, Day S, Green A, et al., 2004, Declining prevalence of STI in the London sex industry, 1985 to 2002, SEXUALLY TRANSMITTED INFECTIONS, Vol: 80, Pages: 374-378, ISSN: 1368-4973
- Author Web Link
- Cite
- Citations: 48
Bobkov AF, Kazennova EV, Selimova LM, et al., 2004, Temporal trends in the HIV-1 epidemic in Russia: Predominance of subtype A, JOURNAL OF MEDICAL VIROLOGY, Vol: 74, Pages: 191-196, ISSN: 0146-6615
- Author Web Link
- Cite
- Citations: 53
Roudinskii NI, Sukhanova AL, Kazennova EV, et al., 2004, Diversity of human immunodeficiency virus type 1 subtype A and CRF03<sub>-</sub>AB protease in eastern Europe:: Selection of the V77I variant and its rapid spread in injecting drug user populations, JOURNAL OF VIROLOGY, Vol: 78, Pages: 11276-11287, ISSN: 0022-538X
- Author Web Link
- Cite
- Citations: 29
Snoeck J, Kantor R, Shafer RW, et al., 2004, Discordances between interpretation algorithms for genotypic resistance to protease and reverse transcriptase inhibitors are subtype dependent, 13th International HIV Drug Resistance Workshop, Publisher: INT MEDICAL PRESS LTD, Pages: U91-U92, ISSN: 1359-6535
Mackie N, Dustan S, McClure MO, et al., 2004, Detection of HIV-1 antiretroviral resistance from patients with persistently low but detectable viraemia, JOURNAL OF VIROLOGICAL METHODS, Vol: 119, Pages: 73-78, ISSN: 0166-0934
- Author Web Link
- Cite
- Citations: 30
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.